about-banner

We are a biopharmaceutical Company pioneering the application of big data analytics and machine learning-based artificial intelligence integrated with drug development expertise, our R&D Engine, to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development.

Our goal is to develop innovative medicines in immuno-oncology, neuroscience, and rare diseases with high unmet need. We believe that our R&D Engine can result in a disruptive change that will impact pharma productivity and innovation to benefit the entire healthcare ecosystem.

We plan to begin a clinical proof-of-concept Phase Ib/II trial for our lead programs, BXCL701, a small molecule immunomodulator for solid tumors and BXCL702, a small molecule immunomodulator for acute myeloid leukemia and other hematological malignancies, both in combination with checkpoint inhibitors. We plan to initiate development of BXCL501 in acute agitation for schizophrenia and bipolar patients with a human proof-of-concept trial under a 505(b)(2) regulatory approval pathway. We plan to partner our program in Neurofibromatosis Type 2 (BXCL101), which has been granted Orphan Disease Designation by the U.S. FDA.

doctor
about-iconab-icon1-hover

Our People

The teams at BioXcel work with excellence, passion, integrity, and mutual respect as they strive to develop a new wave of medicines that will have a significant impact on patients.
about-iconab-icon2-hover

Our Vision

Our vision is to see the application of our R&D Engine resulting in a disruptive change that will impact pharma productivity and innovation to ultimately benefit the entire healthcare ecosystem.
about-iconab-icon3-hover

Our Mission

At BioXcel, we are committed to pioneering the application of artificial intelligence tools and big data analytics to discover and develop the next wave of medicines.

Our Executive Management

  • VIMAL MEHTA, PH.D. Chairman & CEO
  • KRISHNAN NANDABALAN, Ph.D. President & CSO
  • FRANK D. YOCCA, PH.D. Senior VP, CNS R&D
  • LUCA RASTELLI, PH.D. VP, Oncology R&D
  • CHIDS MAHADEVAN VP, Finance and Chief Accounting Officer
  • ANKUSH SETHI Managing Director, India Operations
  • Aman Kant VP, Global Head of Sales & Marketing

Board of Directors

  • ROBIN L. SMITH Chairman, MYnd Analytics
  • DEMETRIOS KYDONIEUS R-Pharm U.S.
  • SANDEEP “STEVE” LAUMAS, M.D. Bearing Circle Capital
  • VIMAL MEHTA, PH.D. Chairman & CEO
  • KRISHNAN NANDABALAN, Ph.D. President & CSO
  • Eric K. Rowinsky Rgenix

Scientific Advisory Board

  • Peter Mueller, Ph.D. Chairman, Scientific Advisory Board
about-banner